info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
us US: +18317045538    uk UK: +441256636046    in IN: +918260836500
Home » Healthcare » Closed System Transfer Devices Market Size, Growth | 2030

Closed System Transfer Devices Market by Device Type (Membrane-To-Membrane Systems, Needleless Systems), Technology (Diaphragm-Based Devices, Compartmentalized Devices, Air Cleaning/Filtration Devices), End Users (Hospitals, Oncology Centers, Other) By Geography, Segment Revenue Estimation and Forecast, 2021-2030

Published On: Dec-2021   |   Base Year: 2021   |   No Of Pages: 135   |   Historical Data: 2017 - 2020   |   Formats: PDF   |   Report ID: 97210565

Report DescriptionTable of Contents

Industry Report and Statistics

The global closed system transfer devices market will witness a robust CAGR of 19.2%, valued at $785.24 million in 2021, expected to appreciate and reach $3.8 billion by 2030, confirms Strategic Market Research. CSTD (Closed System Transfer Devices) is a drug transfer device that prevents the transfer of environmental contamination in the medical systems and escaping hazardous vapor concentrations outside the system. Closed-system transfer devices (CSTDs) are methods used for transferring medication from one reservoir to another while limiting the potential for drug contamination, drug aerosolization, hazardous drug exposure, and sharps exposure. According to a review in 2013, it was discovered that the price of developing a delivery system was only 10% of the total cost of development of a new pharmaceutical. A more recent study in 2020 discovered that the overall price of launching a new drug to market was approximately $985 million, excluding the total cost of developing drug delivery systems. Among the oncologists from all across the world, 65.75% of doctors said that they would prefer chemotherapy to treat cancer. In 2020, approximately 1.8 million new cancer cases were diagnosed, and about 606,520 cancer deaths occurred in the United States. Also, in the United States Each year, almost 650,000 cancer patients receive chemotherapy treatment United States. Some of the most efficient and FDA approved CSTDs include PhaSeal (Bector and Dickinson, US), Arisure (Yukon Medical, US), Tevadaptor (Simplivia Healthcare, Israel), Chemfort (Simplivia Healthcare, Israel), Halo (Corvida, US), ChemoClave (ICU Medical, US), ChemoLock (ICU Medical, US), Equashield II (Equashield, US), NeoShield (JMS, Japan & US).

 

Closed System Transfer Device By Market Share

 

Impact of COVID-19

The COVID-19 pandemic has adversely impacted the CSTD market. Nationwide lockdown and social distancing have caused a deferral of millions of innovative and highly efficient processes, thereby resulting in a potential backlog of case volume. Because of this, the average footfall in hospitals has decreased drastically, and many hospitals postponed non-emergency procedures. In addition, due to the widespread of COVID-19, diagnosis and treatment have become a more significant concern worldwide.

 

Market Drivers: -

The rising number of cancer cases all over the world is one of the prime factors that is driving the growth of this market. It has resulted in a healthy increase in the adoption of chemotherapy treatments worldwide. According to WHO, in 2020, cancer has caused over 10 million deaths across the world. Also, IARC and WHO have estimated that the number of cancer cases all around the world will rise to 19.3 million by 2025.Moreover, a rapid increase in the number of oncology drug approvals is also one of the significant factors that highly stimulate this market's growth efficiently.

 

Restraints: -

The higher price of implementations of CSTDs and a lack of reimbursement policies are the two major factors restraining the overall growth of this market across the world. In addition, many small hospitals don't have the financial capability to purchase this device, owing to which most of them do not opt for CSTDs.

 

Opportunities: -

Cytotoxic drugs are designed to destroy the cells that grow in a rapid and uncontrolled manner. The use of this drug is increasing rapidly in the healthcare sectors across the world and is expected to increase abruptly in the upcoming years. The Cytotoxic Drugs Market size was valued at USD 12.173 million in 2020 and is expected to reach up to USD 20.187 million by 2028, growing at a CAGR of 6.73% 

Also, various non-cytotoxic drugs like Bacillus of Calmette, monoclonal antibodies, and the Guerin strain of Mycobacterium Bovis (BCG) are in high demand and are expected to grow at a rapid rate in the future. 

Closed System Transfer Device Market Based on Technology

Market Analysis Of Different Segments Covered in the Report

Based on Device Type

  • Membrane-To-Membrane Systems Needleless Systems

 

Based on Closing Mechanism

  • Luer-Lock Systems 

  • Color-To-Color Alignment Systems

  • Click-To-Lock Systems

  • Push-To-Turn Systems

 

Based on Technology

  • Diaphragm-Based Devices

  • Compartmentalized Devices

  • Air Cleaning/Filtration Devices

 

Based on Components

  • Vial Access Devices

  • Syringe Safety Devices

  • Bag/Line Access Devices

  • Accessories

 

Based on End Users

  • Hospitals 

  • Oncology Centers

  • Other

 

Regional Coverage Analysis

North America

  • US

  • Mexico

  • Canada

  • Rest of North America

 

Europe

  • Switzerland

  • France

  • U.K 

  • Germany

  • Finland 

  • Netherlands 

  • Russia

  • Belgium 

  • Spain

  • Turkey

  • Italy 

  • Rest of Europe

 

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Malaysia 

  • Singapore 

  • Thailand

  • Australia 

  • Indonesia

  • Philippines 

 

Rest of Asia-Pacific

  • LAMEA

  • Brazil

  • Argentina

  • Uruguay 

  • Saudi Arabia

  • Rest of LAMEA

Closed System Transfer Device Market Based on Region

 

Based on Device Type, the 'Membrane-To-Membrane Systems' segment accounted for the highest share of approximately 70.73% of the CSTDs market. This segment accounted for up to USD 459.1 million in 2020 and is growing rapidly at a CAGR of 20.6%. The biggest share of this segment is due to their ease of operation and a lower risk of contamination associated with Double Membrane Containment Systems.

 

Based on Closing Mechanism, the 'Luer-Lock Systems' segment accounted for the largest share of 33.24 % of the market. This segment is valued at up to USD 213.31 million in 2020, at a CAGR of 19.17%. The 'Color-To-Color Alignment Systems' segment is the fastest-growing segment because of its higher efficiency due to pressure equalization mechanisms and lower cost.

 

Based on Technology, the 'Diaphragm-Based Devices Segment' accounted for the highest share of 42.78% of the market. This segment was valued at up to USD 286.54 million in 2020, at a CAGR of 18.75%. The highest share of this segment is mainly due to the ease of operation and quality of safety provided. The 'Compartmentalized Devices' segment is growing at the fastest rate with a CAGR of 23.57% over the forecast period because of their lower cost.

 

Based on Components, the 'Vial Access Devices' segment held the maximum share of about 32.53 % of the market. The highest percentage of share of this segment is because of the increasing adoption of CSTD products and vial access devices by oncology doctors.

 

Based on End-User, the 'Hospitals & Clinics' accounted for the largest share of 83.71% of the CSTDs market. The largest percentage of this segment is primarily because of the strong financial capacity of the hospitals for purchasing expensive CSTDs, and the urgent need for regulatory guidelines. 

 

Based on Regions, North America held the highest share of the market due to easy accessibility to the advanced and modernized technologies, rising awareness of CSTD among nurses, oncologists, and pharmacists, the existence of many key CSTD manufacturing players in this region, and the continued prevalence of cancer.

 

However, The Asia-Pacific region is growing at the fastest rate with a CAGR of 21.57% over the forecasted period. Continuous increase of cancer cases, increasing demand for better healthcare services, and the focus of key international players such as China and India are fuelling the growth of the Asia Pacific market.

 

Closed System Transfer Device Market Report Coverage

Report Attribute

Details         

Forecast Period

2021 - 2030

The market size value in 2021

USD 785.24 Million

The revenue forecast in 2030

USD 3.8 Billion

Growth rate

CAGR of approximately 19.2%

The base year for estimation

2021

Historical data

2017 – 2021

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

Based on Device Type, Closing Mechanism, Technology, Components, End Users, Based on Regions.

Based on Device Type

Membrane-To-Membrane Systems Needleless Systems

Based on Closing Mechanism

Luer-Lock Systems, Color-To-Color Alignment Systems, Click-To-Lock Systems, Push-To-Turn Systems

Based on Technology

Diaphragm-Based Devices, Compartmentalized Devices, Air Cleaning/Filtration Devices

Based on Components

Vial Access Devices, Syringe Safety Devices, Bag/Line Access Devices, Accessories

End Users

Hospitals, Oncology Centers, Other

By Region

North America, Europe, Asia Pacific, Rest of Asia Pacific

Country Scope

U.S., Canada, France, Germany, U.K., China, Japan, India,  South Korea,  Mexico, Brazil, U.A.E. etc.

Company Usability Profiles

Dickinson and Company, Becton, Corvida Medical, B. Braun Melsungen, ICU Medical, JMS, Equashield, Corvida Medical, Yukon Medical, Simplivia Healthcare, CODAN Medizinische Geräte, Caragen, VICTUS, Baxter International.

Closed System Transfer Device Market Competitive Landscape Analysis

Competitive landscape analysis provides the most accurate details on the notable competitors existing in the market environment all across the world. The comparison is performed based on the global presence, market capability, overall revenue generated, expenditure in the field of R&D, production capacity, market initiatives, company overview and financials, organization flaws and strengths, production sites and facilities, etc.

 

Recent Developments

  • On January 5th, 2021, Simplivia Healthcare obtained a 70% share of NOVAMED, a diagnostic company that efficiently manufactures and develops a range of diagnostic kits to meet the evolving trends of home care adequately.

 

  • On May 18th, 2021, Bector and Dickinson further expanded its drug delivery devices segment by establishing a high-tech manufacturing facility located in Spain.

 

  • On March 2nd, 2021, Yukon Medical launched FDA-approved closed system transfer device Arisure under the ONB product classification.

 

 

Frequently Asked Question About This Report

b: The leading players of this market include Becton, Dickinson and Company, ICU Medical, B. Braun Melsungen, JMS, Simplivia Healthcare, Corvida Medical, Yukon Medical Baxter International, etc.

b: The Closed System Transfer Devices Market Share was valued at USD 785.24 million in 2021 and is expected to reach a landmark of USD 3.8 billion by 2030, with a rapid CAGR of 19.2% over the forecasted period of 2021-2030.

b: The most dominating trends of the CSTD market include automated compounding of hazardous drugs by implementing high-quality robotic systems and the new technologies for rapid detection tests to simulate routine monitoring.

b: Based on Technology, the CSTD market is classified into Diaphragm-Based Devices, Compartmentalized Devices, Air Cleaning/Filtration Devices. The Diaphragm-Based Devices Segment accounted for the highest share of 42.78% of the market. This segment was valued at up to USD 785.24 million in 2021, at a CAGR of 18.75%.

b: North America is the most dominating region of the CSTD market.

b: Based on Technology, the CSTD market is classified into Diaphragm-Based Devices, Compartmentalized Devices, Air Cleaning/Filtration Devices. The Diaphragm-Based Devices Segment accounted for the highest share of 42.78% of the market. This segment was valued at up to USD 785.24 million in 2021, at a CAGR of 18.75%.

b: The closed system transfer devices market size was valued at USD 785.24 million in 2021 and is expected to reach a landmark of USD 3.8 billion by 2030

Sources

https://pubs.rsc.org/en/content/chapterhtml/2015/bk9781782621898-00001?isbn=978-1-78262-189-8

https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html

https://www.who.int/news-room/fact-sheets/detail/cancer